Skip Navigation

JNCI Journal of the National Cancer Institute 2002 94(19):1435-1444; doi:10.1093/jnci/94.19.1435
© 2002 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Shields, P. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Shields, P. G.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of the National Cancer Institute, Vol. 94, No. 19, 1435-1444, October 2, 2002
© 2002 Oxford University Press

REVIEW

Tobacco Smoking, Harm Reduction, and Biomarkers

Peter G. Shields

Correspondence to: Peter G. Shields, M.D., Cancer Genetics and Epidemiology, Lombardi Cancer Center, Georgetown University Medical Center, The Research Bldg., W315, 3970 Reservoir Rd. NW, Washington, DC 20057 (e-mail: pgs2{at}georgetown.edu).

The only known way to reduce cancer risk in smokers is complete cessation, but many smokers are unable or unwilling to quit. Consequently, tobacco companies are now marketing products that purport to reduce carcinogen exposure, with the implication that such products provide a safer way to smoke. Moreover, researchers are exploring ways to reduce the amount of cigarette smoke carcinogens to which the smokers are exposed. Although these methods are, in theory beneficial, it is possible that the perceived availability of "safe" ways to smoke will cause some former smokers to resume smoking and some current smokers to delay quitting. Thus, the extent of exposure reduction and the impact on public health of these methods need to be considered carefully. However, risk reduction and its relation to exposure are not simple to estimate. The way people smoke and the way they respond to carcinogen exposure are both highly variable, as evidenced by the previous history of smokers who switched to light, or low-tar cigarettes. This can actually increase risk in some smokers. The evaluation of exposure reduction will therefore need to be multidisciplinary and include in vitro cell culture studies, animal studies, human clinical studies, and epidemiologic studies. Biomarkers will be critical for rapidly evaluating the effects of new strategies or products to reduce exposure to tobacco smoke carcinogens. No single biomarker will likely satisfy our assessment needs, and so a panel of biomarkers should be used that includes biomarkers of exposure, biologically effective dose, and potential harm. In addition, usefulness of new products will need to be tested in people of different susceptibilities (i.e., who vary in behavior, sex, age, genetics, and prior tobacco use). Even if the new products are shown to be effective at reducing lung carcinogens, they should not be used alone but rather be incorporated into a comprehensive tobacco control program.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Am. J. Respir. Crit. Care Med.Home page
M. Varella-Garcia, L. Chen, R. L. Powell, F. R. Hirsch, T. C. Kennedy, R. Keith, Y. E. Miller, J. D. Mitchell, and W. A. Franklin
Spectral Karyotyping Detects Chromosome Damage in Bronchial Cells of Smokers and Patients with Cancer
Am. J. Respir. Crit. Care Med., September 1, 2007; 176(5): 505 - 512.
[Abstract] [Full Text] [PDF]

Home page
 Toxicol SciHome page
B. Lu, L. Kerepesi, L. Wisse, K. Hitchman, and Q. R. Meng
Cytotoxicity and Gene Expression Profiles in Cell Cultures Exposed to Whole Smoke from Three Types of Cigarettes
Toxicol. Sci., August 1, 2007; 98(2): 469 - 478.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
A. A. Melikian, M. V. Djordjevic, S. Chen, J. Richie Jr., and S. D. Stellman
Effect of Delivered Dosage of Cigarette Smoke Toxins on the Levels of Urinary Biomarkers of Exposure
Cancer Epidemiol. Biomarkers Prev., July 1, 2007; 16(7): 1408 - 1415.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Public HealthHome page
H. A. Tindle, N. A. Rigotti, R. B. Davis, E. M. Barbeau, I. Kawachi, and S. Shiffman
Cessation Among Smokers of "Light" Cigarettes: Results From the 2000 National Health Interview Survey
Am J Public Health, August 1, 2006; 96(8): 1498 - 1504.
[Abstract] [Full Text] [PDF]

Home page
 JAMAHome page
N. S. Godtfredsen, E. Prescott, and M. Osler
Effect of Smoking Reduction on Lung Cancer Risk
JAMA, September 28, 2005; 294(12): 1505 - 1510.
[Abstract] [Full Text] [PDF]

Home page
 Toxicol SciHome page
J. L. Mauderly, A. P. Gigliotti, E. B. Barr, W. E. Bechtold, S. A. Belinsky, F. F. Hahn, C. A. Hobbs, T. H. March, S. K. Seilkop, and G. L. Finch
Chronic Inhalation Exposure to Mainstream Cigarette Smoke Increases Lung and Nasal Tumor Incidence in Rats
Toxicol. Sci., October 1, 2004; 81(2): 280 - 292.
[Abstract] [Full Text] [PDF]

Home page
 Clin Med ResHome page
J. D. Anczak and R. A. Nogler II
Tobacco Cessation in Primary Care: Maximizing Intervention Strategies
Clin. Med. Res., July 1, 2003; 1(3): 201 - 216.
[Abstract] [Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.